Basilea secures extra $5.4M BARDA grant to advance novel antibiotic ceftibuten-ledaborbactam development
Executive summary: Basilea received an additional USD 5.4 million from BARDA to continue development of its novel antibiotic ceftibuten-ledaborbactam. The funding highlights US government commitment to combating antimicrobial resistance and provides Basilea with resources to advance a potential new treatment toward clinical trials and possible market approval.
Who is involved: Basilea (Swiss biotech), BARDA (US Department of Health and Human Services agency), and the antibiotic development program.
Likely next: Basilea will allocate the funds to further preclinical and clinical development steps, with updates on trial progress expected in the coming months.
Basilea announced an additional USD 5.4 million from the US Biomedical Advanced Research and Development Authority (BARDA) to continue work on its experimental antibiotic combination ceftibuten-ledaborbactam. The funding adds to prior BARDA support and underscores the US government’s focus on antibiotic resistance countermeasures. No further details on trial timelines were disclosed in the announcement.
Timeline
- — Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam (GlobeNewswire)
- — Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam (GlobeNewswire)
- — Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix (GlobeNewswire)
Analysis — what this means
Sectors affected
- Antibiotic development
Key entities
Sources
- Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam — GlobeNewswire
- Basilea erhält zusätzliche USD 5.4 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam — GlobeNewswire
- Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix — GlobeNewswire